Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Falls Church, Virginia Clinical Trials

A listing of Falls Church, Virginia clinical trials actively recruiting patient volunteers.

RESULTS

Found (208) clinical trials

Study of ORIC-101 in Combination With Anticancer Therapy

ORIC-101 is a small molecule GR antagonist being developed for the treatment of patients with solid tumor malignancies. Mechanistically, ORIC-101 inhibits GR transcriptional activity and blocks the pro-survival signals mediated by the activated nuclear receptor. This is an open-label, uncontrolled, multicenter, dose-finding study to assess the safety and preliminary antitumor ...

Phase

5.27 miles

Learn More »

A Study of ASP1951 in Subjects With Advanced Solid Tumors

This is a dose-escalation and expansion study of ASP1951. The study consists of 3 periods: screening, treatment and follow up, followed by an optional Re-treatment period for participants that qualify. The escalation cohorts will evaluate escalating dose levels of ASP1951 in participants with locally advanced (unresectable) or metastatic solid tumor ...

Phase

5.27 miles

Learn More »

A Study to Determine the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors

A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 + ABBV-368 with and without ABBV-181 in participants with selected solid tumors. This study consists of 2 main parts, dose-escalation and dose-expansion phases. The trial will begin with dose escalation in Arm A (ABBV-927 + ABBV-368) which ...

Phase

5.27 miles

Learn More »

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Dose escalation of AB928 in combination with carboplatin/pemetrexed and AB928 in combination with carboplatin/pemetrexed plus pembrolizumab at standard doses will be assessed in participants with advanced metastatic non-squamous Non-Small Cell Lung Cancer. In this dose escalation combination study, participants will receive oral administration of AB928 as well as IV infused ...

Phase

5.27 miles

Learn More »

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, an ...

Phase

5.63 miles

Learn More »

PRS-343 in HER2-Positive Solid Tumors

The study will evaluate PRS-343 administered by intravenous (IV) infusion every 3 weeks (Schedule 1) initially. If safety, PK, and PD data suggest a different dosing schedule should be evaluated, Schedule 2 or 3 (dosing every 2 weeks or every 4 weeks in a 28-day cycle, respectively) may be conducted. ...

Phase

5.66 miles

Learn More »

Phase 1 Safety Study of ACT-PFK-158 2HCl in Patients With Advanced Solid Malignancies

ACT-PFK-158 is a novel anti-cancer agent that inhibits glucose uptake in cancer cells. The primary objective of the study will be to determine the maximum tolerated dose (MTD) and to describe any dose limiting toxicity. The secondary objectives of the study will be to determine the safety profile of the ...

Phase

5.66 miles

Learn More »

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab CIS and GEM; and CIS and GEM Alone in Participants With Previously Untreated Unresectable Locally Advanced or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

The study will have a Run-in portion and an Expansion portion. The Run-in portion will be used to evaluate the safety profile of the PEGCISGEM and PEGCISGEMATEZO treatments prior to evaluating the efficacy and safety of PEGCISGEM and PEGCISGEMATEZO treatments compared with CISGEM treatment in the Expansion portion of the ...

Phase

5.66 miles

Learn More »

Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.

This study is a multicenter, open-label, nonrandomized, sequential group, dose-escalation study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ascending doses of AZD5991 in subjects with relapsed or refractory hematologic malignancies. Part 1 of the study is monotherapy dose escalation. Part 2 of the study is monotherapy expansion ...

Phase

5.66 miles

Learn More »

Study to Evaluate a Single Dose of Apixaban in Pediatric Subjects at Risk for a Thrombotic Disorder

CV185118 is a single dose Apixaban PK/PD study in pediatric subjects. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric subjects at risk for thrombosis

Phase

5.66 miles

Learn More »